Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination medication containing three active ingredients: 1. **Lidocaine**: An amide-type local anesthetic with rapid onset but relatively short duration of action. It works by blocking sodium channels in nerve membranes, preventing the generation and conduction of nerve impulses[8]. 2. **Bupivacaine**: A long-acting amide-type local anesthetic with slower onset but extended duration of action compared to lidocaine. Like lidocaine, it blocks sodium channels but provides longer-lasting analgesia[2][9]. 3. **Clonidine**: An alpha-2 adrenergic receptor agonist that, when used as an adjuvant to local anesthetics, can prolong the duration of analgesia. It has been used for many years as an additive to short-, intermediate-, and long-acting local anesthetics[1][5]. The combination is primarily used in peripheral nerve blocks, epidural anesthesia, and other regional anesthetic techniques to provide extended pain relief during and after surgical procedures[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + bupivacaine + clonidine.